Introduction

This report covers the commercialization of stem cells (primarily derived from adult tissues) which are transplanted into patients to improve the function of diseased/damaged tissues/organs. Six indications are covered in detail. Sales forecasts are estimated in the US and five major European markets (5EU), which include France, Germany, Italy, Spain and the UK.

Features and benefits

* Identify potential growth markets with sales forecasts by indication and expected timing of market entry.
* Compare the different business models for stem cell therapies.
* Evaluate which novel products offer the greatest potential clinical advances over the next several years and why.
* Assess potential clinical advances and how they address current unmet needs.
* Understand the drivers and resistors of the stem cell market.

Highlights

Six indications were prioritized based on likely commercial potential and adoption into clinical practice: acute myocardial infarction, heart failure, critical limb ischemia, amyotrophic lateral sclerosis, spinal cord injury and ischemic stroke.
Companies are developing first generation therapies primarily based on ex vivo expanded allogeneic or autologous bone marrow derived stem cells. Recently, a second generation of products has entered clinical development, which may build on the efficacy of first generation products.
The greatest potential revenues are forecast in diseases or conditions with significant mortality or morbidity and limited treatment options, for which autologous bone marrow mononuclear cells (BMMNCs) may not be applicable or ineffective and lower patient numbers can be offset by higher prices.

Your key questions answered

* What is the future commercial value of stem cell therapies?
* Which products are likely to be reimbursed and what price could be charged?
* Which indications offer the greatest sales potential?
* What are the competitive risks to commercialization and how can companies develop profitable business models?
* Which companies are attractive for investment?

Executive Summary
Market overview
Acute myocardial infarction
Heart failure
Critical limb ischemia
Central nervous system disorders
Other indications
Business models and market forecasts
About the author
Disclaimer
Market overview
Summary
Introduction
Market definition
Stem cell types
Adult stem cells
Embryonic stem cells
Clinical landscape
Regulation
European Union
Japan
India
China
Industry overview
Market value
Licensing and merger activity
Conclusions
Acute myocardial infaction
Summary
Introduction
Clinical review
Pipeline analysis
Allogeneic products
Cell processing devices
Market potential
Calculation of addressable population
Market adoption scenario
Future outlook
Heart failure
Summary
Introduction
Clinical review
Ongoing trials using BMMNCs or MSCs
Other stem cells types
Mechanism of action
Pipeline analysis
Autologous products
Allogeneic products
Market size
Future outlook
Critical limb ischemia
Summary
Introduction
Clinical review
Pipeline analysis
Autologous products
Allogeneic products
Cell processing devices
Market size
Future outlook
Central nervous system disorders
Summary
Introduction
Amyotrophic lateral sclerosis
Spinal cord injury
Ischemic stroke
Future outlook
Other indications
Summary
Introduction
Graft versus host disease
Solid organ transplants
Diabetes mellitus
Chronic obstructive pulmonary disease
Inflammatory bowel disease
Acute kidney injury
Alzheimer's disease
Parkinson's disease
Multiple sclerosis
Business models and market forecasts
Summary
Introduction
Key success factors
Acute versus elective conditions
Regulatory considerations
Stem cell quality
Manufacturing process
Clinical trial design
Business models
Allogeneic product models
Autologous product models
Device based models
Pricing and reimbursement
Sales forecasts to 2025
Future outlook
Appendix
Scope
Methodology
Abbreviations
References